Atlas Trials

Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients

Clinical trial NCT03874000 · UNKNOWN

Trial details

NCT number
NCT03874000
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer
Start date
2019-03-08
Primary completion
2022-02-28
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.